Hi GLA,
Thank you - It is a very quiet thread, but I would expect that if the thread was active, then the SP would be considerably higher.
Yes, I did focus on a revenue comparison (versus EBIT) as this was an easier metric to communicate. Some of the peer group capitalises Research & Development (AZV expenses R&D) and they reside in different jurisdictions with different accounting standards (eg GAAP versus AABS).
In essence the re-structuring process entailed closing down Perth based manufacturing and shifting across to Dallas, USA manufacturing. The difference is cost base is substantial - it the order of $AUD28 / hour (fully loaded costs) versus closer to $USD12 / hours (full loaded). However, this triggered substantial redundancy costs and parallel of production lines, resulting in an interruption of supply lines over this time period - virtually impossible to shift manufacturing from one country to another with causing a level of delays. Understanding this process, I waited until the transition was complete, but prior to the full cost benefits to trickle down to the bottom line - hence the timing of my investment.
Additionally, the company divested a non-core asset (CellGuard), which generated a decrease in revenues as a result, but enabled the company to focus on its core, healthcare interests. A prudent decision, but resulted in a loss of revenue from this segment.
I have every confidence with the re-structuring (having done exactly the same process in my own electronics business in 2007, which operating in an identical market segment). I have known the business for 30 years, so I have a pretty good understanding of the segment
I would expect that in FY19, the Company will likely get back to a 15%-18% EBITDA, in line with its peer group.
The company has a history of not communicating to shareholders particularly well, however I suspect that the board would be hesitant to spend funds on Investor Relations until such time as the transition was complete, all the one-off costs incurred and written off, to provide a clean slate moving forward.
- Forums
- ASX - By Stock
- Azure Healthcare Revisited
Hi GLA, Thank you - It is a very quiet thread, but I would...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AHC (ASX) to my watchlist
(20min delay)
|
|||||
Last
18.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $64.93M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 53189 | 18.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
19.0¢ | 99597 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 53189 | 0.180 |
3 | 225700 | 0.175 |
2 | 85000 | 0.170 |
4 | 146000 | 0.165 |
1 | 125000 | 0.160 |
Price($) | Vol. | No. |
---|---|---|
0.190 | 99597 | 4 |
0.200 | 103897 | 1 |
0.205 | 5000 | 1 |
0.210 | 100000 | 1 |
0.240 | 5641 | 1 |
Last trade - 16.12pm 28/06/2024 (20 minute delay) ? |
Featured News
AHC (ASX) Chart |
Day chart unavailable
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online